相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10-or 11-day intervals with filgrastim support in women with breast cancer
Monica N. Fornier et al.
CLINICAL CANCER RESEARCH (2007)
Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era
Mariantonietta Colozzaa et al.
ONCOLOGIST (2006)
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer
George Fountzilas et al.
MEDICAL ONCOLOGY (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas et al.
ANNALS OF ONCOLOGY (2005)
Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
A Goldhirsch et al.
ANNALS OF ONCOLOGY (2005)
Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer
A Eniu et al.
ONCOLOGIST (2005)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
EP Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Treatment of Wilms tumor: An international perspective - Reply
D Green
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
J Tabernero et al.
ANNALS OF ONCOLOGY (2004)
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
CT Dang et al.
CLINICAL CANCER RESEARCH (2004)
Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer
EA Wist et al.
ACTA ONCOLOGICA (2004)
Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience
J Crown et al.
ONCOLOGIST (2004)
Dose density in adjuvant chemotherapy for breast cancer
ML Citron
CANCER INVESTIGATION (2004)
Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)
K Sato et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2003)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Weekly paclitaxel in women age 65 and above with metastatic breast cancer
EA Perez et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
FJ Esteva et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
